摘要
目的探讨血清促红细胞生成素(erythropoietin,EPO)、可溶性转铁蛋白受体(soluble transferrin receptor,sTfR)水平和癌性贫血之间的关系,为临床合理使用重组人红细胞生成素(Recombinant Human Erythropietin,r-HuEPO)和铁剂治疗癌性贫血提供理论依据。方法采用酶联免疫分析方法(ELISA)测定60例癌性贫血患者血清EPO水平和sTfR水平,并将其与52例非癌性贫血患者的测定值及20例正常对照进行比较,以直线相关分析sTfR、EPO水平和Hb之间的关系。结果癌性贫血患者血清EPO、sTfR均较正常对照显著升高(P<0.01);癌性贫血患者血清EPO显著高于非癌性贫血患者(P<0.05);癌性贫血患者sTfR高于非癌性贫血患者,差异无显著性(P>0.05);癌性贫血患者血清EPO、sTfR升高的程度与贫血严重程度一致,与Hb值存在负相关,但与病期无明显相关性;EPO和sTfR之间无相关性。结论恶性肿瘤患者的血清EPO和sTfR水平能较好地反映其贫血病因,对贫血的治疗以及预后判断有一定的临床参考价值。
Objective To explore the relationship between the levels of erythropoietin（EPO）,soluble transferrin receptor（sTfR） in serum and cancer-related anemia,and provide the evidences for the treatment with rHuEPO and chalybeate in patients with cancer-related anemia.Methods The levels of EPO and sTfR in serum were detected by a sensitive enzyme-linked immunosorbent assay（ELISA） technique in 60 patients with cancer-related anemia,52 patients with non-cancer-related anemia and 20 normal controls.The relationship between EPO,sTfR and Hb was analyzed with the linear correlation method.Results The levels of EPO and sTfR in patients with cancer-related anemia were significantly higher than those in normal control（P0.01）.The level of EPO in cancer-related anemia patients′serum was significantly higher than that in non-cancer-related anemia patients′serum（P0.05）,but the level of sTfR was not significantly different between the two groups.A negative correlation was found between the levels of EPO,sTfR and Hb concentration in cancer-related anemia patients.The degree of increase in levels of EPO,sTfR was parallel to the severity of anemia.Both of them had no correlation with the stages of disease.No correlation was proved between EPO and sTfR.Conclusion The levels of EPO and sTfR in cancer-related anemia patients can help the doctors to find out etiological factors,choose treatment and predict prognosis of the disease.
出处
《中国肿瘤临床与康复》
2010年第2期107-110,共4页
Chinese Journal of Clinical Oncology and Rehabilitation
